What's Happening?
AbbVie has announced a $195 million investment to expand its active pharmaceutical ingredient (API) production capabilities in North Chicago. This expansion is part of AbbVie's broader commitment to invest over $10 billion in the US to support innovation and enhance manufacturing capacity. The new facility will bolster AbbVie's chemical synthesis capabilities, supporting the domestic production of current and next-generation medicines in neuroscience, immunology, and oncology. Construction is set to begin in fall 2025, with the facility expected to be fully operational by 2027.
AD
Why It's Important?
AbbVie's investment in US API production is a significant step in maintaining the country's leadership in pharmaceutical innovation. By expanding domestic manufacturing capabilities, AbbVie aims to support future medical breakthroughs and deliver next-generation medicines that impact patients' lives. This investment also strengthens AbbVie's commitment to Illinois, where it is headquartered, and supports thousands of jobs across its US manufacturing sites and suppliers. The expansion aligns with broader industry trends emphasizing the importance of local production in ensuring supply chain resilience and innovation.
What's Next?
The construction of the new API facility will begin in fall 2025, with operations expected to commence in 2027. AbbVie plans to expand production of API, drug products, peptides, and medical devices in the US over the next decade. This expansion will likely lead to increased collaboration with suppliers and partners, fostering innovation and supporting the development of new therapies. The investment may also prompt other pharmaceutical companies to enhance their domestic manufacturing capabilities, contributing to the growth of the US pharmaceutical industry.
